SARASOTA, Fla.--(BUSINESS WIRE)--May 7, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that it has teamed with Altura, LLC of Aliso Viejo, CA to expand its research and product development efforts to address a number of undisclosed prescription drugs.
Altura will provide DNAPrint with clinically phenotyped samples for an undisclosed class of drugs, and DNAPrint will use the samples for population genomics research aimed at developing chemopredictive tests for an individualization of therapy. Drugs of the class targeted by the agreement exhibit markedly variable response rates and adverse events in the patient population. Because of this, a significant number of patients are exposed to unnecessary health risks for long periods of "treatment" time until the right drug and/or dose is found through trial and error. Due to the size of the market for the class of drugs, the agreement could have substantial implications for the company's quest to grow long-term earnings potential.
The agreement will compliment DNAPrint's current collection efforts, and enhance DNAPrint's multi-drug consent databank by 500 patients over the course of 2002. Last year, DNAPrint successfully completed a similar project with Pharsight corporation (Nasdaq:PHST), but DNAPrint continues to collect most of its specimens using its own private network of Florida physicians. The agreement expands to 18 the list of FDA-approved drugs for which DNAPrint is now developing pharmacogenomics classifiers, or chemopredictive tests.
With this agreement, DNAPrint gains access to Altura's expertise, which include project planning, implementation, obtaining IRB approval and collecting qualified specimens and relevant clinical data from patients throughout the US who are taking selected medications. Due to their large number of clinical relationships and knowledge of organized health systems, Altura is particularly adept at collecting data and enrolling large number of patients and physicians in an efficient manner. Terms of the agreement remain undisclosed.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit dnaprint.com.
About Altura, LLC:
Altura provides a variety of development and implementation services to the healthcare, clinical research, pharmaceutical, medical device and biotech industries. The company's focus is on facilitating the effective conduction of health outcomes programs, clinical studies and business development activities. Altura's in-depth knowledge of organized systems of healthcare, study sponsors, regulatory requirements and the clinical research industry allow for a unique offering of standard or customized services. For more information about Altura please visit altura2000.com or contact Pete Fronte, President, at 949-330-6160.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400
ccastillo@dnaprint.com |
